Biogen

IRS: 330112644
BIIB
Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.

Founded
1978 (42 years)
CEO
Michel Vounatsos
Investor RelationsSEC
Revenue
14 billion (2020)

Want to see more? Sign up!